Home » Stocks » MYOK

MyoKardia, Inc. (MYOK)

Nov 16, 2020 - MYOK was delisted after being acquired by BMY
Stock Price: $224.91 USD 0.00 (0.00%)
Updated Nov 17, 2020 4:00 PM EST

Stock Price Chart

Key Info

Market Cap 11.99B
Revenue (ttm) 12.40M
Net Income (ttm) -276.96M
Shares Out 53.32M
EPS (ttm) -5.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Nov 17, 2020
Last Price $224.91
Previous Close $224.91
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 224.52 - 225.00
Day's Volume 0
52-Week Range 42.65 - 225.00

More Stats

Market Cap 11.99B
Enterprise Value 11.15B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 53.32M
Float 51.76M
EPS (basic) -5.63
EPS (diluted) -5.66
FCF / Share -4.00
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.63M
Short Ratio 2.02
Short % of Float 8.94%
Beta 1.83
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 967.17
PB Ratio 14.19
Revenue 12.40M
Operating Income -283.18M
Net Income -276.96M
Free Cash Flow -212.26M
Net Cash 847.01M
Net Cash / Share 15.88
Gross Margin -1,823.96%
Operating Margin -2,283.70%
Profit Margin n/a
FCF Margin -1,711.76%
ROA -23.07%
ROE -42.70%
ROIC -83.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 0
Overweight 0
Hold 6
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$215.00*
(-4.41% downside)
Low
135
Current: $224.91
High
225
Target: 215.00
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue-33.5611.4441.9714.205.92-
Revenue Growth-193.29%-72.74%195.59%140.01%--
Gross Profit-33.5611.4441.9714.205.92-
Operating Income-288-73.65-58.67-10.53-23.21-17.22-13.63
Net Income-276-67.70-57.01-10.38-22.95-16.83-12.70
Shares Outstanding44.7738.3932.8327.486.291.761.17
Earnings Per Share-6.17-1.76-1.74-0.38-4.48-11.30-11.98
Operating Cash Flow-242-64.82-9.84-20.86-32.1013.66-12.53
Capital Expenditures-3.26-3.37-1.51-1.08-1.31-0.72-1.17
Free Cash Flow-245-68.19-11.35-21.94-33.4112.94-13.70
Cash & Equivalents41831725714011243.651.91
Total Debt0.38------
Net Cash / Debt41831725714011243.651.91
Assets45640728320111746.894.70
Liabilities49.8236.6952.1355.9222.7132.212.56
Book Value40637123114593.87-36.91-17.25
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name MyoKardia, Inc.
Country United States
Employees 318
CEO Anastasios E. Gianakakos

Stock Information

Ticker Symbol MYOK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MYOK
IPO Date October 29, 2015

Description

MyoKardia, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.